Weight-loss injections are not PMOS cure; experts caution against self-medication
With drugs belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class gaining attention for weight management, specialists have cautioned that women with PMOS need an individualised treatment plan based on their symptoms, weight, metabolic health and reproductive goals.
Weight-loss injections, specifically those belonging to the GLP-1 receptor agonist class, can help some women with Polyendocrine Metabolic Ovarian Syndrome (PMOS) manage their excess weight and related metabolic issues, but they are not a cure for the hormonal disorder, according to experts. Gynaecologist and IVF Specialist Dr Hrishikesh Pai warns that these medications should not be used without medical supervision, as PMOS is a complex condition that requires an individualized treatment plan based on symptoms, weight, metabolic health, and reproductive goals.
Endocrinologist Dr Kunal Gupta adds that the decision to prescribe these medicines should be based on an assessment of the patient's body weight, blood sugar levels, insulin resistance, and other associated risk factors, and that benefits may not persist after treatment discontinuation if lifestyle changes are not maintained.
Brief written by urgent.news from ETHealthworld's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
